Evolution of viral variants in remdesivir‐treated and untreated SARS‐CoV‐2‐infected pediatrics patients-Reference-Cited by-同舟云学术

Evolution of viral variants in remdesivir‐treated and untreated SARS‐CoV‐2‐infected pediatrics patients

Published:2021-09-04 Issue:1 Volume:94 Page:161-172
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Boshier Florencia A. T.¹,Pang Juanita¹²,Penner Justin³,Parker Matthew⁴,Alders Nele³,Bamford Alasdair³,Grandjean Louis¹,Grunewald Stephanie⁵,Hatcher James⁶,Best Timothy⁶,Dalton Caroline⁷,Bynoe Patricia Dyal¹,Frauenfelder Claire⁸⁹,Köeglmeier Jutta¹⁰,Myerson Phoebe¹,Roy Sunando¹,Williams Rachel¹,Silva Thushan I.⁴,Goldstein Richard A.²,Breuer Judith¹⁶,

Affiliation:

1. Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health University College London London UK

2. Division of Infection and Immunity University College London London UK

3. Department of Infectious Disease Great Ormond Street Hospital for Children NHS Foundation Trust London UK

4. Department of Infection, Immunity and Cardiovascular Diseases, The Florey Institute University of Sheffield Sheffield UK

5. Department of Metabolic Medicine UCL Great Ormond Street Institute of Child Health London UK

6. Department of Microbiology Great Ormond Street Hospital for Children NHS Foundation Trust London UK

7. Department of Pharmacy Great Ormond Street Hospital for Children NHS Trust London UK

8. Department of Ears Nose and Throat, Great Ormond Street Hospital for Children NHS Foundation Trust London UK

9. Division of Surgery University of Adelaide Adelaide South Australia Australia

10. Department of Gastroenterology Great Ormond Street Hospital for Children NHS Foundation Trust London UK

Funder

Medical Research Council

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27285

Reference50 articles.

1. WHO Coronavirus Disease (COVID‐19) Dashboard. Accessed February 23 2021.https://covid19.who.int

2. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

3. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

4. Compassionate Use of Remdesivir for Patients with Severe Covid-19

5. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance;Frontiers in Science;2024-04-25

2. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients;Nature Communications;2024-02-23

3. Variant-specific humoral immune response to SARS-CoV-2 escape mutants arising in clinically severe, prolonged infection;2024-01-07

4. Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient;Virology Journal;2023-10-27

5. Remdesivir Use in the Real-World Setting: An Overview of Available Evidence;Viruses;2023-05-14